Hormonal
During the menopausal transition and early postmenopause, sleep symptoms (difficulty falling asleep, nighttime awakening, early morning awakening) are significantly associated with vasomotor symptoms (hot flashes), psychological distress (depressed mood, anxiety), and perceived health, rather than being driven solely by hormonal changes like FSH or estradiol levels.
If you are experiencing sleep issues during menopause, look beyond just hormone levels. Address hot flashes, manage stress, and monitor your mood, as these factors are strongly linked to sleep quality. Improving your overall perceived health and managing vasomotor symptoms may be more effective for sleep than focusing on hormonal markers alone.
Multivariate models for each symptom included hot flashes, depressed mood, and perceived health. Severity of self-reported problems going to sleep was associated with all symptoms, perceived stress, history of sexual abuse, perceived health (-), alcohol use (-) (all P < 0.001)... Severity of nighttime awakening was significantly associated with age, late MT stage. and early PM, FSH, E1G (-), hot flashes, depressed mood, anxiety, joint pain, backache, perceived stress, history of sexual abuse, perceived health (-), and alcohol use (-)... Severity of early morning awakening was significantly associated with age, hot flashes, depressed mood anxiety, joint pain, backache, perceived stress, history of sexual abuse, perceived health (-)...
Why this rating
Longitudinal cohort study (SWAN-derived context) with rigorous multilevel modeling and objective biomarkers, though observational.
Source
Sleep Symptoms During the Menopausal Transition and Early Postmenopause: Observations from the Seattle Midlife Women's Health Study
Nancy Fúgate Woods et al. · SLEEP · 2010
DOI 10.1093/sleep/33.4.539
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →